4.1 Review

The changing epidemiology of Clostridium difficile infection

期刊

CURRENT OPINION IN GASTROENTEROLOGY
卷 30, 期 1, 页码 54-62

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOG.0000000000000018

关键词

Clostridium difficile; diagnosis; epidemiology; treatment

资金

  1. Optimer
  2. Viropharma
  3. Sanofi- Pasteur
  4. Merck

向作者/读者索取更多资源

Purpose of reviewClostridium difficile infection (CDI) is a growing concern and has a substantial impact on morbidity and mortality. Epidemiology of CDI has dramatically changed over the last decade. Diagnostic and treatment strategies are even more complicated given the wide variety of available diagnostic methods and the emergence of refractory or recurrent CDI. This review is intended to provide information on current CDI epidemiology and guidance for evidence-based diagnosis and management strategies.Recent findingsVarious studies from the United States, Europe, and Canada revealed increased incidence of CDI since 2000. Although CDI has long been associated with healthcare settings, recent studies indicate it is more common in the community than previously recognized. For diagnostic strategies, newer testing methods, including nucleic acid amplification tests, have enhanced sensitivity compared with toxin testing, but at the expense of decreased specificity. New agents for treating CDI are being developed and higher quality data to support fecal microbiota transplantation for treating recurrent CDI are emerging.SummaryCDI epidemiology continues to evolve. Prompt recognition and an evidence-based treatment approach is the key to successfully manage CDI. Further, studies on diagnostic and therapeutic strategies are needed to further improve patient outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据